Johnson & Johnson is a global healthcare company operating across two segments: Innovative Medicine (pharmaceuticals, ~63% of revenues) and MedTech (medical devices, ~37% of revenues). Innovative Medicine develops and sells branded prescription drugs across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular. Oncology is the largest and fastest-growing area, anchored by DARZALEX, J&J's single biggest product with over $14B in annual sales, which is the standard of care in multiple myeloma. The immunology business is anchored by TREMFYA, which is expanding into inflammatory bowel disease and is J&J's designated successor to STELARA, which is losing revenue rapidly to biosimilar competition. Neuroscience is growing fast, led by SPRAVATO for treatment-resistant depression, bolstered by the $14.5B acquisition of Intracellular Therapies and its drug CAPLYTA. MedTech sells devices across cardiovascular, surgery, vision, and orthopedics. Cardiovascular is the fastest-growing MedTech area, built around EP mapping and ablation systems, Abiomed's Impella heart pumps, and Shockwave's intravascular lithotripsy technology. MedTech's business model relies on placing capital equipment in hospitals and generating recurring revenue from consumables and disposables. J&J reinvests heavily in R&D and M&A to replace drugs approaching patent expiration, and is targeting $50B in oncology revenue by 2030. J&J plans to spin off its orthopedics business to focus MedTech on higher-growth areas including cardiovascular, surgical robotics, and vision.